Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function

To evaluate the effects of canagliflozin on the renal oxygen level and blood perfusion in newly diagnosed type 2 diabetes mellitus (T2DM) patients with normal renal function. We conducted a prospective, randomised, and drug-controlled trial to determine the reno-protective effect exerted by canagliflozin in newly diagnosed T2DM patients with normal renal function using blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) and arterial spin labelling MRI (ASL-MRI). This provides an experimental basis for a first-line of defence for the prevention of diabetic nephropathy. Canagliflozin induced a significant decrease in body weight and diastolic blood pressure compared with glimepiride (all p < 0.05). The high baseline mean estimated glomerular filtration rate (eGFR) in both groups was indicative of a GFR level at a relatively high status that was significantly alleviated after 24 weeks of canagliflozin treatment (change from baseline, p = 0.04, and change versus glimepiride control, p = 0.048). However, neither drug regimen significantly affected renal blood perfusion. The R2* values were inversely proportional to the tissue oxygen content. Compared to the baseline, 24 weeks of canagliflozin treatment decreased the R2* values of the renal cortex and medulla by 22.3% (p = 0.005) and 29.2% (p = 0.0002) respectively, and these decreases were significantly greater than in the glimepiride control group (p = 0.0004 and p = 0.02). Canagliflozin improved the levels of renal oxygenation in newly diagnosed T2DM patients with normal renal function independent of changes in renal blood perfusion.